OrthoPediatrics Q4 2022 Earnings Report
Key Takeaways
OrthoPediatrics Corp. announced its Q4 2022 financial results, with revenue increasing by 25% year-over-year to $31.0 million. The company experienced growth in both domestic and international markets, driven by its core businesses and recent acquisitions. However, the company reported a net loss of $7.8 million for the quarter.
Q4 2022 revenue increased 25% year-over-year to $31.0 million.
Domestic revenue increased 15% and international revenue increased 67% in Q4 2022.
Full year 2022 revenue increased 25% year-over-year to $122.3 million.
The company helped nearly 17,000 children in Q4 2022 and approximately 70,000 for the full year.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Forward Guidance
OrthoPediatrics expects full year 2023 revenue to be in the range of just over $146.0 million to $149.0 million, representing growth of 20% to 22% over 2022 revenue. The guidance assumes roughly $5.0 million of combined revenue contribution from MD Ortho and Pega Medical before the acquisitions become organic on their anniversaries. The Company also expects its annual set deployment to be approximately $25.0 million and expects to generate $3.0 million to $4.0 million of adjusted EBITDA for full year 2023.
Positive Outlook
- Revenue growth of 20% to 22% is expected for full year 2023.
- Revenue to be in the range of just over $146.0 million to $149.0 million
- Roughly $5.0 million of combined revenue contribution from MD Ortho and Pega Medical
- Annual set deployment to be approximately $25.0 million
- Adjusted EBITDA to generate $3.0 million to $4.0 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income